EMA Grants Orphan Drug Status to UAB's Maresin-1 Therapy for Spinal Cord Injuries
Key Insights
The European Medicines Agency has designated Maresin-1 (search) (MaR1 (search)), a bioactive lipid molecule, as an orphan drug for treating spinal cord injuries, recognizing its potential clinical benefit in an area with high unmet medical need.
MaR1 (search) demonstrated outstanding capacity in animal models to significantly reduce post-injury inflammation and promote processes that limit neurodegeneration, translating into substantial improvement in locomotion recovery.
The orphan drug designation provides regulatory advantages including priority scientific advice and accelerated evaluation pathways, though clinical trials are still 3-5 years away pending completion of preclinical studies.
The European Medicines Agency (EMA) has granted orphan drug designation to Maresin-1 (search) (MaR1 (search)), a bioactive lipid molecule being developed by researchers at Universitat Autònoma de Barcelona (UAB) for treating spinal cord injuries. The designation recognizes that MaR1 could provide relevant clinical benefit in an area with significant unmet medical need.
Addressing Critical Medical Need
Spinal cord injuries affect an estimated 20 to 45 cases per million inhabitants annually, yet no pharmacological treatment currently exists to improve neurological recovery after injury. The only drug approved for acute-phase treatment is methylprednisolone, which many countries discourage due to its adverse effects and limited efficacy.
Mechanism and Preclinical Results
MaR1 (search) is a lipid naturally produced by macrophages during the resolution phase of inflammation. It functions to promote termination of inflammatory processes and tissue protection. The UAB research team, led by Rubèn López-Vales from the Neuroplasticity and Regeneration Group of the Institut de Neurociències (INc-UAB) and the Department of Cell Biology, Physiology and Immunology, has demonstrated the compound's therapeutic potential in animal models.
In preclinical studies, MaR1 (search) showed outstanding capacity to significantly reduce post-injury inflammation and promote processes that limit neurodegeneration. These biological effects translated into substantial improvement in locomotion recovery in animal models.
"This designation is the recognition of many years of research in the biology of inflammation resolution and in spinal cord injury models and allows us to move forward towards the goal of one day being able to offer therapy to people affected by this serious condition," said López-Vales.
Regulatory Pathway Forward
The EMA's orphan drug designation provides several regulatory advantages designed to accelerate compound development, including priority scientific advice and accelerated evaluation pathways. The designation also protects marketing exclusivity should the treatment reach market approval.
Before advancing to clinical trials, the research team must complete regulatory preclinical studies supporting product safety and establish a fully validated manufacturing process. Additionally, they must secure approval from regulatory agencies and ethics committees for their submitted documentation. These preparatory steps are expected to require approximately 3 to 5 years before patient trials can commence.
The UAB research is supported by funding from the Spanish Ministry of Science, Innovation and Universities, the "la Caixa" Foundation, the Agency for the Management of University and Research Grants (AGAUR), Barcelona Activa, and university funds.